Pfizer will sell two Novartis drugs in the UK.
After weeks of speculation as to whether MannKind would find a marketing partner for its inhalable insulin, the drugmaker said today that Sanofi would acquire global licensing rights to the drug for $925 million.
The painkiller's marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.
A two-year study shows Gilead's Quad pill outpaces an older combination drug over two years, and GSK is seeking to expand its oncology presence.
Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn't sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief
GlaxoSmithKline returned marketing rights on epilepsy drug Horizant to XenoPort effective April 30, 2013.
Auxilium inked a co-promote deal with GSK on its Testim 1% testosterone gel for the US.
WebMD the Magazine is now part of the iPad app world.
Amylin said it will hire 365 sales reps to make up for Eli Lilly's departure from commercial activities, once the firm takes full control of the exenatide diabetes franchise in the US this month.
Vertex has succeeded in bringing one heck of a new drug to market in Incivek (in-SEE-veck, or telaprevir), a hepatitis C drug 15 years in the making which promises to cut treatment time in half. Selling the drug against the combined might of Roche and Merck could be nearly as tricky.
Roche will help promote Merck's newly approved hepatitis C drug Victrelis (boceprevir) under a strategic partnership that may help bolster the firms' chances in an upcoming market share battle. The agreement stunned Wall Street, since Merck and Roche already sell rival versions of a standard hepatitis C treatment.
Lilly/Boehringer Ingelheim's third-to-market DPP-4 inhibitor Tradjenta, approved earlier this week for the treatment of type 2 diabetes, faces an uphill battle for market share against Merck's entrenched market leader Januvia and BMS/AstraZeneca's Onglyza.
Teva is partnering with Procter & Gamble in an OTC drug marketing joint venture that will boast annual sales of more than $1 billion -- and which could ultimately be worth four times that, the companies say.